Evidence map›Paper›PMID 37348833›Full record

Observational studyValue in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research2023

Comparisons of Medical Cost Trajectories Between Non-Hispanic Black and Non-Hispanic White Patients With Newly Diagnosed Localized Prostate Cancer.

Yu Liu, Shikun Wang, Liang Li, Ying Xu, Yu Shen, Ya-Chen Tina Shih

Open access · bronzeAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yu LiuDepartment of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Public Health, College of Health Sciences Sam Houston State University, Huntsville, TX.
Shikun WangDepartment of Biostatistics, Columbia University, New York City, NY, USA.
Liang LiDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ying XuDepartment of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yu ShenDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ya-Chen Tina ShihDepartment of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: yashih@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USColumbia University · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Estimating the Cost Trajectories and Projecting the Cost of Cancer Care in the United States: Methodology and ApplicationR01CA225646 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LI, LIANG, SHIH, YA-CHEN TINA · 2018 to 2022
$1.8M
Technology Diffusion in Cancer: Geographic Variations, Facilitators, Outcomes, and CostsR01CA207216 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHIH, YA-CHEN TINA · 2016 to 2020
$1.6M
NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA207216NCI NIH HHS R01 CA225646
6 · The paper itself

Abstract

objectivesThis study applied a recently developed statistical method to compare the mean cost trajectories between non-Hispanic White (NHW) and non-Hispanic Black (NHB) patients with localized prostate cancer conditioning on patients' survival.

methodsIn this observational study, we modeled cost trajectories of NHW and NHB patients with localized prostate cancer for 3 survival durations: 24, 48, and 72 months. We also compared the cost trajectories between NHW and NHB, stratified by comorbidities scores.

resultsWe find that the mean cost trajectories of NHB were significantly higher than the trajectories of NHW in the last 12 months before death, regardless of the survival duration and patients' baseline comorbidity scores. For patients with comorbidity score ≥2, mean cost trajectories within the first year of diagnosis for NHB were significantly higher than those for NHW, except for the subgroup of patients with comorbidity 2-3 and whose survival length was 72 months.

conclusionsOur results suggested that a higher proportion of NHB patients with high comorbidity scores are likely contribute to their higher end-of-life costs than those for NHW patients. To narrow the gap in healthcare-related financial burden between NHB and NHW patients with localized prostate cancer, policy makers need to explore different strategies to better manage comorbidities.

Indexed as

Health Care CostsProstatic NeoplasmsBlack or African AmericanEthnicityHumansMaleWhitechronic diseasehealthcare costshealthcare disparities

Identifiers

PMID37348833
PMCPMC10527436
OpenAlexW4381332819

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.